Akantior (polihexanide)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- polihexanide
- Company
- SIFI SPA
- Status
- Authorised
- Therapeutic area
- Acanthamoeba Keratitis
- CHMP opinion
- Thu 30 May 2024
- EU approval
- Thu 22 Aug 2024
- Designations
- Orphan
- Application
- EMEA/H/C/005858
- ATC
- S01AX24
- Official record
- www.ema.europa.eu
Indication
Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age.
Regulatory milestones
No milestones recorded in the last year.
Follow Akantior
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.